Clinical trial for Gynecologic Cancers
Official title A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
ClinicalTrials.gov ID: NCT07024784
What this study is testing
What is IMGN151?
IMGN151 is an investigational medicine being studied as a potential treatment for gynecologic cancers.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how safe and tolerable IMGN151 is when used by itself or together with other cancer medicines.
- Who it's for
- Adults who have gynecologic cancers such as ovarian, fallopian tube, or primary peritoneal cancer.
- What's involved
- Participants will get an IV infusion of IMGN151, either alone or combined with carboplatin, olaparib, or bevacizumab, plus regular blood tests, scans, and clinic visits.
- Time commitment
- The trial lasts about three years with frequent visits to the hospital or clinic for assessments.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- ECOG performance status of 0 or 1
- Participants (except for platinum-sensitive ovarian, fallopian tube, and primary peritoneal cancer (PSOC) participants without disease progression...
- Participants will have high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC).
- Systemic antineoplastic therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of IMGN151.
- Focal radiation completed ≥ 2 weeks prior to the first dose of study treatment.
You likely can't join if
- Participants with ovarian cancer with histologies including: endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing...
- History of clinically significant medical conditions or any other reason that the investigator determines would interfere with the participant's...
- Prior treatment with FRα-targeting therapy.
- Prior wide-field radiotherapy affecting more than 20% of the bone marrow.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Aurora, Colorado, United States
- Minneapolis, Minnesota, United States
- Teaneck, New Jersey, United States
- Syracuse, New York, United States
- Cincinnati, Ohio, United States
- Cleveland, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Portland, Oregon, United States
- Providence, Rhode Island, United States
- Nashville, Tennessee, United States
- Austin, Texas, United States
- Fairfax, Virginia, United States
- Petah Tikva, Central District, Israel
- Ramat Gan, Tel Aviv, Israel
- Tel Aviv, Tel Aviv, Israel
- Haifa, Israel
- Jerusalem, Israel
- Akashi-shi, Hyōgo, Japan
- Chuo-Ku, Tokyo, Japan
+ 1 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Aurora, Colorado, United States; Minneapolis, Minnesota, United States; Teaneck, New Jersey, United States; Syracuse, New York, United States; Cincinnati, Ohio, United States and 15 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.